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Abstract
In early December 2019, in the city of Wuhan in Hubei Province, China, the first infections by a novel coronavirus were reported. 
Since then, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has been spreading to other cities and countries 
becoming the global emerging epidemiological issue and quickly reaching the status of a pandemic. Multiple risk factors of 
disease severity and mortality have been identified so far. These include old age, male sex, smoking, and obesity. This concise 
narrative review highlights the important role of these factors in the pathobiology and clinical landscape of Coronavirus Disease 
2019 (COVID-19). We especially focused on their significant role in disease severity and mortality. However, in spite of intensive 
research, most of the presented pieces of evidence are weak and need further verification. 
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Introduction
In early December 2019, in the city of Wuhan 
in Hubei Province, China, the first infections 
by a novel coronavirus were reported. The new 
pathogen was named severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) and the 
disease in which it is an etiological factor for was 
named coronavirus disease 2019 (COVID-19) [1]. 
Since then, SARS-CoV-2 has been spreading to 
other cities and countries becoming the global 
emerging epidemiological issue and quickly 
reaching the status of a pandemic. On the 4th 
of March, the first SARS-CoV-2 positive patient 
was officially confirmed by the Polish Ministry of 
Health [2]. Since that time, morbidity and mor-
tality have been increasing across the country. 
The key to effective treatment of these pa-
tients is to increase knowledge about the patho-
biology of the disease which does not seem to be 
fully understood so far. 
Multiple risk factors of disease severity and 
mortality have been identified so far. These in-
clude old age, male sex, smoking, and obesity 
[3–8]. Therefore, in our considerations, we decid-
ed to cover these issues in the broad and multi-
faceted context of interactions, mainly focusing 
on its interference with the immunopathological 
background of COVID-19. We attempted to sum-
marize the current state of knowledge and draw 
some hypotheses for further research in order 
to raise questions and open up a debate about 
analyzed issues. Figure 1 summarizes the main 
points discussed in the manuscript.
Beyond age…
Ageing may be defined as a progressive de-
cline in tissue homeostasis due, at least in part, 
to the accumulation of replicative, oxidative, and 
genotoxic stress over time [9]. An increasing body 
of evidence suggests that ageing is associated 
with chronic inflammation, both pathological 
and physiological. 
Multiple causes may contribute to ageing- 
-associated inflammation such as pro-inflam-
matory tissue damage, a dysfunctional immune
system, proinflammatory cytokines secreted
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by senescent cells, enhanced Nuclear Factor 
kappa-light-chain-enhancer of activated B cells 
(NF-κB) activation, and a defective autophagy 
response. These factors enhance the activation of 
inflammatory pathways (i.e. the nod-like recep-
tor 3 (NLRP3) inflammasome) and then induce 
the production of cytokines such as interleukin 
(IL)-1β, tumor necrosis factor alpha (TNF-α), and 
interferons (IFNs). Long term inflammation could 
be a major cause of ageing-associated diseases 
[10]. In the SARS-CoV-2 infection, viroporin 
3a has also been shown to trigger the activa-
tion of the inflammasome NOD 3-like receptor 
protein (NLRP3) and the secretion of IL-1β in 
bone marrow macrophages. This condition may 
result in an increased release of a large number 
of pro-inflammatory agents. Reports suggest that 
a storm of cytokines is released in patients with 
SARS-CoV-2 disease which is mainly manifested 
by increased IL-2, IL-7, granulocyte colony stimu-
lating factor (GC-SF), monocyte chemo-attracting 
protein 1 (MCP1), and TNF-α. Of all the interleu-
kins, IL-6 has been found to be associated with 
highly pathogenic SARS-CoV-2 infection due to 
Figure 1. Graphical summary of the manuscript (author: AJ Białas)
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increased viral replication mainly in the lower 
respiratory tract [11, 12].
Telomere-controlled cellular ageing
The inflammatory process associated with 
telomere-controlled cellular ageing can lead to 
reduced tissue regenerative capacity. This is prob-
ably due to the impairment of stem and progenitor 
cell functions. 
A telomere is a region of tandem repeats of 
short DNA sequences at the ends of chromosomes 
which are important for their stability and allow 
for the complete replication of the ends [13, 14]. 
The telomere proteome consists of more than 
200 proteins that are associated with different 
aspects of telomere functioning including their 
protection, elongation, or telomeric DNA synthesis 
[13–16]. Telomere length homeostasis is essential 
for the proper functioning of the cell [14, 17]. Telo-
meres are also an important element in the ageing 
of cells. As well, they are involved in maintaining 
immune homeostasis. They are also the main indi-
cator of biological age and are a measurable marker 
of both inflammation and oxidative stress [10].
Normal ageing is, by itself, associated with 
telomere shortening. A significant shortening of 
telomeres leads to cell death. The speed of short-
ening can be further increased by inflammation 
and oxidative stress and thus, affects the ageing 
process. In addition, cell telomere shortening 
may be associated with an increase in NF-κB 
transcription factor activity and overexpression 
of inflammatory cytokines such as TNF-α, IL-6, 
and IFN-γ in circulating macrophages [10, 18]. 
NF-κB is a family of seven transcription factors 
(p50, p52, p100, p105, RelA/p65, RelB, and C-Rel) 
and plays a central role in inflammation and cell 
response by controlling gene network expression 
[19, 20]. Activation of NF-κB is redox-sensitive 
and can be regulated by the changes in the ox-
idant/antioxidant balance [19]. The members 
of this family may activate expression of many 
pro-inflammatory genes which also play a role in 
lung inflammation [19, 21]. This evidence justifies 
the reports about upregulation of NF-κB activity in 
both naturally aged mice and multiple progeroid 
mouse models of accelerated ageing [9].
The generation gap?
The specific vulnerability of older people to 
severe COVID-19 disease is well documented. 
However, let us discuss why children seem to be 
more protected.
Scarpa et al. suggest that the essential role of 
the thymus could be crucial in the modulation of 
the immune response toward SARS-CoV-2 lead-
ing to a less severe phenotype in children when 
compared with adult COVID-19 patients. They 
identify inflammaging associated with the absence 
of thymopoietic mechanisms as a potentially 
predisposing condition that sustains the surge 
of proinflammatory cytokines that is specifically 
reported in older COVID-19 patients [22]. Indeed, 
severe adult COVID-19 pneumonia cases are as-
sociated with a decrease in regulatory T cells and 
CD4+/CD8+ T cells [23]. Since the thymus is the 
primary lymphoid organ essential for the develop-
ment of T lymphocytes, its decreased functioning 
could lead to a drastic decrease in these T cells 
[24]. Moreover, one of the age-related changes in 
the immune system is the impaired generation of 
primary T cell responses against infection [24, 25].
Some facts about fats…
White adipose tissue is an active endocrine 
organ consisting of mature and developing ad-
ipocytes, endothelial cells, and immune cells 
such as adipose tissue macrophages, neutrophils, 
eosinophils, mast cells, and T and B cells. Thus, 
people with a normal body weight have a balance 
between adipocytes and immune cells which 
maintains tissue homeostasis. In particular, eo-
sinophils and T-regulatory cells (Tregs) secrete 
anti-inflammatory cytokines (IL-10 and IL-4) that 
direct adipose tissue macrophages towards the an-
ti-inflammatory phenotype, thereby maintaining 
a tolerogenic environment. This condition is also 
associated with the production of adiponectin, 
which increases insulin sensitivity [26, 27].
In turn, obesity causes adipocyte prolifer-
ation which leads to increased leptin secretion 
and infiltration of inflammatory cells. Adipocyte 
hypoxia and cellular stress were able to induce 
the expression of chemoattractant molecules with 
a consistent recruitment of macrophages, T cells, 
and B cells. When T cells are activated, the num-
ber of Treg cells is reduced [28]. The phenotype 
of macrophages changes from M2 to M1, which in 
turn accumulate around adipocytes and produce 
large amounts of proinflammatory cytokines such 
as TNF-α. In addition, obesity is characterized by 
a dysregulated secretion of adipokines such as 
leptin, adiponectin, LCN2, and PGRN which have 
become key regulators of the innate and adaptive 
immune systems [27, 28].
There is a lot of evidence showing a worse 
prognosis in obese patients infected with the 
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SARS-CoV-2 virus, especially among young peo-
ple. It should also be mentioned that obesity is 
a well-known risk factor for respiratory diseas-
es. Excessive growth of fat leads to hyperactiva-
tion of interleukin-6 and chronic inflammation 
which increases the risk of acquiring comor-
bidities such as diabetes and hypertension [27]. 
Again, both hypertension and diabetes are listed 
among the most prevalent risk factors for a worse 
prognosis in SARS-CoV-2 infection [12, 27].
When discussing the relationship between 
the inflammatory process and obesity in the 
SARS-COV-2 infection, we also have to discuss 
the role of mitochondria.
Generally speaking, mitochondria are mul-
tifunctional cellular organelles which play an 
important role in numerous aspects of cell mor-
phology and physiology such as the synthesis of 
adenosine triphosphate (ATP), intracellular trans-
fer of energy, redox homeostasis, regulation of 
cellular metabolism [29], cellular calcium homeo-
stasis, synthesis of steroids [30], and apoptosis 
[31, 32]. However, mitochondria also play a key 
role in initiating inflammatory pathways. Mito-
chondrial dysfunction drives the ageing process 
by reducing cellular fitness, inflicting damage 
to other organelles, and/or causing mutations 
of the nuclear genome. One critical mechanism 
underlying the dysfunction of mitochondria is 
the accumulation of mutations and deletion of 
aged mitochondrial DNA (mtDNA), which is 
a consequence of the decline in mitochondrial 
autophagy (mitophagy). This process seems to 
decline in ageing individuals as the expression 
of several key components is decreased [33]. 
The dysfunction of mitophagy leads to the accu-
mulation of damaged mitochondria, which then 
initiates inflammasomes and other inflammatory 
pathways. Mitochondria are essential for the 
NLRP3 inflammasome activation because they 
can activate NLRP3 inflammasomes by producing 
ROS. Furthermore, ROS-mediated mitochondrial 
permeability transition facilitates the release of 
mtDNA, which can stimulate pro-inflammatory 
signaling via the pattern recognition receptors 
RIG-I and MDA5, promoting the activation of NF-
κB and interferon regulatory factors [33]. 
Based on the available data for SARS-CoV-2, 
its RNA is also located in mitochondria. It is 
postulated that SARS-CoV-2 transcripts found 
in mitochondria may affect mitochondrial func-
tion via ACE2 to avoid host cell immunity and 
to facilitate viral replication and COVID-19 dis-
ease [34]. Additionally, manipulation of host 
mitochondria by viral open-reading frames can 
release mitochondrial DNA (mtDNA) in the cy-
toplasm which can potentially serve as a potent 
danger-associated molecular pattern and can 
activate mtDNA-induced inflammasomes. This, 
in turn, can suppress both innate and adaptive 
immunity [33, 35]. 
Evil, damned evil and cigarette smoking…
The commonly accepted mechanism of 
SARS-CoV-2 cell entry is via use of the angioten-
sin converting enzyme 2 (ACE 2) receptor [36]. 
Some earlier papers suggested that smoking and 
nicotine are strong factors down-regulating ACE 
2 expression [37]. Contrarily, results of current 
studies on airway epithelia are different [38, 
39]. A potential adhesion site for SARS-CoV-2 is 
up-regulated in smokers independent of coex-
isting COPD. In the lung, SARS-Cov-2 infection 
and down-regulation of ACE2 receptors leads 
to increased angiotensin II activity that direct-
ly causes uncontrolled inflammation and lung 
damage [40, 41]. Although it has been suggested 
that an increase in the expression of ACE2 may 
contribute to the severe form of SARS-CoV-2-in-
duced infection, it actually might be beneficial. 
Thus, looking for a prevalence of past or current 
smokers among COVID-19 patients might explain 
the important question both from a practical and 
theoretical point of view. Observational studies 
in China and in Italy have suggested that ARDS 
among smoking COVID patients is less prevalent 
than in patients who never smoked [42, 43]. The 
convincing meta-analysis of updated results from 
China confirms that active smoking is significant-
ly associated with a risk of severe COVID-19 [44].
Smoking is strongly accompanied by neutro-
philic airway inflammation [45]. SARS-CoV-2 in-
fection induces biphasic immune responses. In 
the incubation stage, both innate and adaptive 
immunity are responsible for virus elimination. 
Therefore, inflammation can be limited, and the 
disease does not develop. Nearly 80% of infected 
people are only carriers of the infection [46]. 
In the second phase, when the protective 
response is diminished, the virus will propagate. 
Tissues damage develops following inflammation 
that is mostly mediated by neutrophils and mac-
rophages and is especially noticeable in organs 
rich in ACE 2 receptors such as the lungs and 
kidneys. This cytokine storm seems to be mainly 
attributed to interleukin 6 [47]. 
There is no doubt that neutrophilic inflam-
mation can be evoked and amplified by different 
factors. Smoking and other forms of indoor or 
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outdoor air pollution are two factors in the pub-
lic space that can evoke neutrophilic infiltration 
of the lungs. Air pollutants have been shown 
to be important factors influencing both virus 
transmission and COVID development [48]. It 
is logical that the inflammatory process is am-
plified by smoking in severe stages of COVID. 
Controversies can arise, however, if nicotine, 
the stable constituent of cigarettes, is found to 
be protective against COVID progression. Nic-
otine has been found to be an agent that can 
prevent the onset of Acute Respiratory Distress 
Syndrome in animal models [49]. Nicotine has 
some anti-inflammatory properties due to agonis-
tic cholinergic action [50]. Moreover, it inhibits 
the production of IL-6 and some other cytokines 
with no influence on interleukin-10 release [51]. 
Nicotine is approved by the FDA for medical 
use, but with many contraindications. Nicotine’s 
mechanism of action might explain the contro-
versies surrounding the influence of smoking on 
COVID initiation [52, 53]. However, emerging 
data indicate that both past and especially current 
smoking is an important determinant of worsen-
ing COVID-19 outcomes. This can have a positive 
effect on patients trying to quit smoking because 
the potential severity of the infection combined 
with the general knowledge about the harmful 
influence of smoking creates a situation where 
patients may consider smoking cessation. In fact, 
during the pandemic, many smokers tried to quit 
their smoking habit [54–56].
For individuals who use e-cigarettes, it is 
important to remember that they also have many 
harmful properties and can create a real hazard 
for future smoking addiction [57]. Heat-not-burn 
(HNB) tobacco products produce aerosol like 
traditional cigarettes, but with a lower level of 
harmful constituents, including carcinogens. It 
is important to remember that the impact of HNB 
products on population-level risk reduction will 
be maximized if smokers completely switch to 
the product (and abandon cigarettes). Individuals 
who use these products will find that their daily 
nicotine exposure remains stable or is reduced. 
That being said, the product will only reduce pop-
ulation-level risk if it does not attract non-smokers 
[58, 59]. To date, no study on vaping or HNB prod-
uct use during COVID is available and discussing 
the possible result of replacing cigarette smoking 
with less harmful products is pure speculation. 
However, it seems logical that in smokers in whom 
all methods of smoking cessation were ineffective, 
new and different methods for combatting tobacco 
addiction should be explored.
To sum up this part of our considerations, 
it is evident that smoking promotes the progress 
of COVID-19. Paraphrasing Mark Twain, one can 
say that “there is evil, damned evil and ciga-
rette smoking”. Because of sociopsychological 
circumstances, the SARS-CoV-2 pandemic is an 
opportune time for smoking cessation in addicted 
people. The potential anti-inflammatory activity 
of nicotine does not seem to be significant see-
ing as the majority of studies show smoking as 
a promoting factor in the SARS-CoV-2 infection. 
However, nicotine replacement therapy (patches, 
gums) might be used during cessation therapy 
because of possible anti-inflammatory properties 
and a small risk of potential side effects. During 
smoking cessation, all known methods (i.e. psy-
chosocial support, cytisine, varenicline) can be 
used. In smokers unable to quit smoking tradi-
tional cigarettes using these methods, using HNB 
products instead of traditional cigarettes may 
be recommended. According to a report by an 
independent study of Polish people trying to quit 
smoking, 50% of HNB product users achieved 
success. This is more than users of e-cigarettes, 
where only 25% of individuals succeeded. More-
over, in many young people, nicotine dependence 
starts from the use of e-cigarettes [23]. We do 
not recommend e-cigarettes since the balance 
of potential advantages and disadvantages from 
a public health point of view is negative. 
When the lungs wear the pants…
Sex seems to be an interesting issue in the 
context of COVID-19. Notably, recent survival 
analysis performed by Li et al. revealed that 
male sex was one of the significant risk factors 
associated with death in patients with severe 
COVID-19 [6]. Chen et al., in their early report 
from Wuhan, also reported that those who died 
in their cohort were more likely to be male [4]. 
Similarly, higher risks have been reported for men 
in the Italian population [7]. Another study by 
Jin et al. focused purely on gender differences in 
patients with COVID-19 in the context of severity 
and mortality and concluded that while males and 
females have the same prevalence, men infected 
with COVID-19 are at a greater risk for worse 
outcomes and death, independent of age [8]. 
In terms of analysis, we should initially ex-
amine differences in the expression of ACE2 by 
gender. Notably, it is activated and down-reg-
ulated by the spike protein of the virus which 
allows for the penetration of SARS-CoV-2 into 
epithelial cells and the myocardium. There is 
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evidence suggesting that hypertensive male 
mice have a spontaneously higher myocardial 
ACE2 expression than females, and that its levels 
decrease after orchiectomy [60]. This observation 
is concordant with the strong body of evidence 
indicating that ACE2 expression and activity may 
be influenced by sex hormones [61–65]. In light 
of this evidence, La Vignera et al. suggested that 
testosterone (or LH/hCG) administration could 
be temporarily discontinued or given at a lower 
posology in patients with hypogonadism, while 
estrogen replacement therapy may be considered 
in hypogonadal and postmenopausal women [60]. 
Male vulnerability to COVID-19 may be fur-
ther enhanced by X-linked inheritance of genetic 
polymorphisms seeing as loci of both androgen 
receptors and ACE2 genes are located on the 
X chromosome [66].
On the other hand, ACE2 is also expressed 
in the testes (in spermatogonia, Leydig cells, and 
Sertoli cells) [67–69]. Ma et al. found that the level 
of serum luteinizing hormone (LH) was signifi-
cantly increased, but that the ratio of testosterone 
to LH and the ratio of follicle stimulating hormone 
to LH was significantly decreased in males with 
COVID-19. This evidence, showing disturbances 
in male gonadal function, indicates the need for 
an increased focus on the evaluation of gonadal 
function among patients who have recovered 
from the SARS-CoV-2 infection, especially in 
reproductive-aged men [67]. 
Another interesting issue in the context of 
sex is transmembrane serine protease 2 (TM-
PRSS2) which is a critical factor in enabling 
cellular infection by coronaviruses, including 
SARS-CoV-2. Notably, androgen receptor activity 
seems to be required for the transcription of the 
TMPRSS2 [66, 70]. 
In turn, McCoy et al. hypothesized that 
androgen receptor genetic variants associated 
with prostate cancer and androgenetic alopecia 
would be associated with racial variations in 
COVID-19 mortality. Authors also suggest that 
the use of anti-androgens like bicalutamide and 
enzalutamide or androgen modulators like fin-
asteride and dutasteride may be beneficial [71].
Additionally, we have to emphasize that an 
increasing body of evidence indicates that there 
are dimorphic immune response differences to 
viral infections between males and females. These 
differences are unfavorable for males, who pres-
ent with a higher mortality rate in epidemiolog-
ical studies. Indeed, females mount a stronger 
immune response to viral infections due to more 
robust humoral and cellular immune responses. 
It is suggested that estrogen and testosterone dif-
ferentially alter expression of genes involved in 
innate immunity (i.e. those encoding TLRs and 
interferons) thereby contributing to sexual dimor-
phism in the response to viral infections. These 
issues may also contribute to sex differences in 
the natural history of COVID-19.
However, most of the above-mentioned issues 
are just hypotheses and should be further verified. 
This is especially true in terms of the specific 
roles and levels of androgens in the pathobiology 
of COVID-19. 
Conclusions 
This review highlights the important role of 
ageing, sex, and smoking in the pathobiology and 
clinical landscape of COVID-19. We especially 
focused on their significant role in disease sever-
ity and mortality. However, in spite of intensive 
research, most of the presented pieces of evidence 
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